Component
Human platelet cPLA2-to-NF-kappaB signaling axis
Species, preparation, dose and limitations are retained on linked claims.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Eugenol reduced collagen-stimulated IKK and p65 phosphorylation and I-kappaB-alpha degradation; inhibitor ordering placed cPLA2 upstream of NF-kappaB in human platelets.
Experimental context and source evidence
- dose
- Eugenol with CAY10502 or BAY11-7082 pathway probes
- duration
- Acute
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- evidence_scope
- literature_reviewed; model-specific source-derived curation
- experimental_model
- Platelets from healthy human donors; mouse mesenteric-thrombosis arm
- limitations
- Anucleate platelet NF-kappaB signaling and mouse plug formation do not establish chronic human outcomes.
- nutrient_topic
- Eugenol chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Eugenol
- organism
- Platelets from healthy human donors; mouse mesenteric-thrombosis arm
- plain_language
- Eugenol reduced collagen-stimulated IKK and p65 phosphorylation and I-kappaB-alpha degradation; inhibitor ordering placed cPLA2 upstream of NF-kappaB in human platelets.
- primary_references
- Eugenol: A Potential Modulator of Human Platelet Activation and Mouse Mesenteric Vascular Thrombosis via an Innovative cPLA2-NF-κB Signaling Axis. (2024). https://pubmed.ncbi.nlm.nih.gov/39200154/ DOI: 10.3390/biomedicines12081689
- route
- In vitro and in vivo mouse model
- tissue
- cPLA2 and NF-kappaB signaling
Eugenol: mechanism of action and interactions (2026-09-20) · lines 33–42
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Platelets from healthy human donors; mouse mesenteric-thrombosis arm · source_derived_draft · unverified_draft
## eugenol-cpla2-nfkb Eugenol reduced collagen-stimulated IKK and p65 phosphorylation and I-kappaB-alpha degradation; inhibitor ordering placed cPLA2 upstream of NF-kappaB in human platelets. Model/species: Platelets from healthy human donors; mouse mesenteric-thrombosis arm Tissue/system: cPLA2 and NF-kappaB signaling Exposure: Eugenol with CAY10502 or BAY11-7082 pathway probes Route: In vitro and in vivo mouse model Duration: Acute Limits: Anucleate platelet NF-kappaB signaling and mouse plug formation do not establish chronic human outcomes. Primary reference: Eugenol: A Potential Modulator of Human Platelet Activation and Mouse Mesenteric Vascular Thrombosis via an Innovative cPLA2-NF-κB Signaling Axis. (2024). https://pubmed.ncbi.nlm.nih.gov/39200154/ DOI: 10.3390/biomedicines12081689 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.